Nassar, Amin H.
Mouw, Kent W.
Jegede, Opeyemi
Shinagare, Atul B.
Kim, Jaegil
Liu, Chia-Jen
Pomerantz, Mark
Harshman, Lauren C.
Van Allen, Eliezer M.
Wei, Xiao X.
McGregor, Bradley
Choudhury, Atish D.
Preston, Mark A.
Dong, Fei
Signoretti, Sabina
Lindeman, Neal I.
Bellmunt, Joaquim
Choueiri, Toni K. http://orcid.org/0000-0002-9201-3217
Sonpavde, Guru
Kwiatkowski, David J.
Article History
Received: 5 July 2019
Revised: 25 September 2019
Accepted: 8 October 2019
First Online: 20 December 2019
Ethics approval and consent to participate
: The study was initiated after approval from the GELB committee. The Dana-Farber Cancer Institute Institutional review boards (IRB) approval was obtained under protocol DF/HCC 11-104 and was conducted in accordance with the Declaration of Helsinki. A Dana-Farber Cancer Institute approved written informed consent was obtained from all patients.
: Not applicable.
: The datasets supporting the conclusions of this article are included within the article and its InternalRef removed.
: Guru Sonpavde: consultant for BMS, Exelixis, Bayer, Sanofi, Pfizer, Novartis, Eisai, Janssen, Amgen, Astrazeneca, Merck, Genentech, EMD Serono and Astellas/Agensys; Research support to the institution from Astrazeneca, Bayer, Amgen, Boehringer-Ingelheim, Janssen, Merck, Sanofi and Pfizer; Author for Uptodate; Steering committee for Astrazeneca, BMS, Bavarian Nordic and Astellas; Speaker for Onclive; Research to Practice; Physician Education Resource (PER). Lauren C. Harshman reports consulting fees from Genentech, Dendreon, Pfizer, Medivation/Astellas, Exelixis, Bayer, Kew Group, Corvus, Merck, Novartis, Michael J. Hennessy Associates (Healthcare Communications Company and several brands such as OncLive and PER), Jounce and EMD Serono; Research funding from Bayer, Sotio, Bristol-Myers Squib, Merck, Takeda, Dendreon/Valient, Jannsen, Medivation/Astellas, Genentech, Pfizer and Endocyte (Novartis), and support for research travel from Bayer and Genentech. David J. Kwiatkowski reports serving as a consultant for Novartis. Eliezer Van Allen reported serving as an advisor or consultant for Tango Therapeutics, Genome Medical, Invitae, Illumina, Foresite Capital and Dynamo. He receives research support from Novartis, BMS; has equity in Tango Therapeutics, Genome Medical, Syapse and Microsoft; receives travel reimbursement from Roche/Genentech; holds institutional patents on ERCC2 mutations and chemotherapy response, chromatin mutations and immunotherapy response, and methods for clinical interpretation. Toni K. Choueiri reported receiving institutional and personal funds from Analysis Group, AstraZeneca, Alexion, Bayer, Bristol-Myers-Squibb/ER Squibb and sons LLC, Cerulean, Eisai, Foundation Medicine Inc., Exelixis, Ipsen, Tracon, Genentech, Roche, Roche Products Limited, F. Hoffmann-La Roche, GlaxoSmithKline, Lilly, Merck, Novartis, Peloton, Pfizer, Prometheus Labs, Corvus, Calithera, Sanofi/Aventis and Takeda; reported receiving honoraria from the Analysis Group, AstraZeneca, Alexion, Sanofi/Aventis, Bayer, Bristol-Myers-Squibb/ER Squibb and sons LLC, Cerulean, Eisai, Foundation Medicine Inc., Exelixis, Genentech, Roche, Roche Products Limited, F. Hoffmann-La Roche, GlaxoSmithKline, Heron Therapeutics, Lilly, Merck, Novartis, Peloton, Pfizer, EMD Serono, Prometheus Labs, Corvus, Ipsen, Up-to-Date, NCCN, Analysis Group, NCCN, Michael J. Hennessy (MJH) Associates, Inc. (Healthcare Communications Company with several brands such as OnClive, PeerView and PER), L-path, Kidney Cancer Journal, Clinical Care Options, Platform Q, Navinata Healthcare, Harborside Press, American Society of Medical Oncology, NEJM and Lancet Oncology; having a consulting or advisory role at Analysis Group, AstraZeneca, Alexion, Sanofi/Aventis, Bayer, Bristol-Myers-Squibb/ER Squibb and sons LLC, Cerulean, Eisai, Foundation Medicine Inc., Exelixis, Genentech, Heron Therapeutics, Lilly, Roche, GlaxoSmithKline, Merck, Novartis, Peloton, Pfizer, EMD Serono, Prometheus Labs, Corvus, Ipsen, Up-to-Date and NCCN. No speaker's bureau. No leadership or employment in for-profit companies. Other present or past leadership roles: director of GU Oncology Division at Dana-Farber and past president of medical staff at Dana-Farber, member of NCCN Kidney panel and the GU Steering Committee and past chairman of the Kidney Cancer Association Medical and Scientific Steering Committee. Patents, royalties or other intellectual properties: International Patent Application No. PCT/US2018/12209, entitled “PBRM1 Biomarkers Predictive of Anti-Immune Checkpoint Response,” filed January 3, 2018, claiming priority to U.S. Provisional Patent Application No. 62/445,094, filed January 11, 2017; International Patent Application No. PCT/US2018/058430, entitled “Biomarkers of Clinical Response and Benefit to Immune Checkpoint Inhibitor Therapy,” filed October 31, 2018, claiming priority to U.S. Provisional Patent Application No. 62/581,175, filed November 3, 2017. Travel, accommodations and expenses, in relation to consulting, advisory roles or honoraria. Medical writing and editorial assistance support may have been funded by Communications companies funded by pharmaceutical companies (ClinicalThinking, Envision Pharma Group, Fishawack Group of Companies, Health Interactions, Parexel and others). The institution (Dana-Farber Cancer Institute) may have received additional independent funding of drug companies or/and royalties potentially involved in research around the subject matter. CV provided upon request for scope of clinical practice and research. Kent W. Mouw reports consulting fees from Pfizer, EMD Serono and OncLive, as well as research funding from Pfizer.
: Not applicable.